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Human papillomavirus (HPV) appears to be the
most ubiquitous of the human viruses. Over 100
HPV types have been identi®ed. A minority of HPV
cause cutaneous warts and mucosal condylomata.
The HPV that cause mucosal condylomata put the
patient at various degrees of risk for developing
cancers, particularly cervical cancer. The majority of
HPV infect the skin of normal and immunocompro-
mised individuals. In normal people, most of these
HPV appear to establish a latent infection of the
skin, most likely as normal ¯ora residing in hair
follicles; however, in patients with various systemic
and localized depressions of cell-mediated immunity,
some HPV infections appear to be involved in the
development of nonmelanotic skin cancer and its
precursor lesions in skin, usually in sunlight-exposed
areas. Circumstantial evidence suggests that these
HPV may have a role in promoting proliferative
lesions of the skin, although their sites of active
infection and mode of transmission to susceptible
individuals remain unknown. Key words: condylomata/
human papillomavirus/papillomas/skin cancer/squamous car-
cinoma. Journal of Investigative Dermatology Symposium
Proceedings 6:203±206, 2001
H
uman papillomaviruses (HPV) are small DNA
tumor viruses that cause cutaneous warts and
mucosal condylomata (Schlegel, 1990; Shah and
Howley, 1990; Jenson and Lancaster, 1991;
P®ster and Fuchs, 1994; zur Hausen and de
Villiers, 1994; Tyring, 2000). HPV infect basal cells of
susceptible squamous epithelium. Type-speci®c infections are
restricted by the biologic function of the squamous epithelium
at different anatomic sites. Although active infections by HPV
are associated with the development of familiar, benign
cutaneous warts and mucosal condylomata, latent infections
appear to occur most frequently on mucosal surfaces (Ferenczy
et al, 1985; Steinberg et al, 1983) and in hair follicles (Boxman
et al, 1997, 1999a,b, 2000; Schenkel et al, 1999). Only HPV
capable of establishing latent infections appear to impart various
degrees of malignant potential to susceptible individuals. Over
100 HPV genotypes have been identi®ed by molecular analysis
of the viral genome, which is subdivided into three functionally
distinct regions: the long control region (LCR), the early
region, and the late region (Baker, 1987). Most genotypes are
represented clinically by serotypes that re¯ect the antibody
response to neutralizing, conformational epitopes formed by
tertiary folding of the variable domains of the major capsid (L1)
protein (Cowsert et al, 1987; Ghim et al, 1992; Christensen et
al, 1994; Hines et al, 1994). The L1 gene constant domains are
highly conserved and their translation into similar amino acid
sequences provides the basis for the infrastructure of the viral
capsid (Chen et al, 1998).
CUTANEOTROPIC AND MUCOSOTROPIC HPV AND
THEIR MALIGNANT POTENTIAL
Of the known HPV types, at least 75% are cutaneotropic. Only a
few cutaneotropic HPV actually induce cutaneous warts (common
warts, plantar warts, and ¯at juvenile warts) in immunocompetent
individuals. The remaining cutaneotropic HPV appear to inhabit
healthy skin as normal ¯ora, presumably by latently infecting hair
follicles (P®ster, personal communication). Only after suppression
of systemic cell-mediated immunity or downregulation of the local
immune response of the skin will some of the latent HPV infections
become clinically apparent, frequently as disseminated or localized
pityriasiform-like lesions (Jablonska et al, 1997; Favre et al, 1998).
Patients with epidermodysplasia verruciformis (EV), an autosomal
recessive disease characterized by various degrees of depressed cell-
mediated immunity, develop carcinomas associated with several
HPV (HPV-5 and -8 in particular). The other EV HPV and the
more recently discovered novel HPV have not been directly
associated with malignancies; however, the recent identi®cation of
these HPV by polymerase chain reaction (PCR) and neutralizing
antibodies against these HPV in kidney transplant patients with
nonmelanotic cutaneous carcinomas and in normal individuals with
squamous carcinoma and precursor lesion and solar keratosis, has
focused attention on the malignant potential of the HPV that
appear to constitute normal ¯ora (de Villiers et al, 1997, 1999;
Berkhout et al, 2000).
The mucosotropic HPV have various degrees of carcinogenic
potential that are fairly well de®ned for each virus type. Some, such
as HPV-16 and -18, are high-risk viruses that cause 50% and 25% of
cervical cancers, respectively (Lorincz et al, 1992; Bosch et al, 1995).
HPV-31, -33, and -35 put the patient at intermediate risk. The
remainder of the mucosotropic HPV (HPV-6 and -11) appear to
impart little if any risk to most patients. All carcinogenic HPV appear
to require cofactors to develop into cancers (zur Hausen, 1999). The
highest-risk types require less clinically obvious cofactors. One of the
low-risk types, HPV-11, causes cancer of the respiratory tract,
particularly the larynx (Abramson et al, 1987), after irradiation.
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HPV INFECTION
Warts and condylomata produce the HPV virions responsible for
horizontal or vertical transmission or reinoculation (Jenson and
Lancaster, 1991). Reinoculation of adjacent squamous epithelium
by productively infected warts and condylomata may be a much
more common cause of persistent HPV-induced lesions than
previously realized. Prophylactic vaccines may be able to eradicate
genital condylomata (Schiller and Lowy, 1996; Breitburd and
Coursaget, 1999), something that could not be accomplished if the
lesions were being regenerated by latent infections (Jenson,
unpublished data). Virions are formed when the viral genome is
encapsidated by structural viral proteins in the nuclei of terminally
differentiated keratinocytes (Jenson and Lancaster, 1991). Virions
appear to become embedded in desiccated cellular debris before
being shed either directly or indirectly to areas of similar squamous
epithelium on susceptible individuals. The keratinaceous debris
may protect encased virions from the external environment for
long periods. It may also allow virions to penetrate cracks and
crevices of susceptible squamous epithelium to infect basal
keratinocytes. HPV virus particles appear to be capable of attaching
to, binding with, and entering into almost any living cell (Roden et
al, 1994; Muller et al, 1995); however, replication of the virus
depends on the interaction between the virus LCR and the
intracellular milieu of site-restricted basal keratinocytes.
HPV TRANSMISSION
HPV are transmitted either directly or indirectly from warts and
condylomata to susceptible human hosts. Transmission of HPV by
direct contact includes horizontally transmitted mucosotropic
HPV, the most common sexually transmitted disease (Ferenczy
and Jenson, 1996). Vertically transmitted laryngeal papillomatosis
occurs in susceptible infants exposed to HPV-11-induced venereal
warts (Steinberg, 1988; Kashima et al, 1996). Although never
proven epidemiologically, there appears to be an age distribution
for indirect transmission that re¯ects shared activities in different
age groups (Jenson and Lancaster, 1991); e.g., crawling and
transmission of HPV-3-induced verruca plana from the scraped
surface of one child's knees to those of another, the occurrence of
HPV-2-induced verruca vulgaris in adolescents who share brace-
lets, and the appearance of HPV-1-induced verruca plantaris in
young adults walking barefoot around swimming pools and on
diving boards or sharing communal shower stalls.
IMMUNOLOGIC RESPONSE TO HPV INFECTION
Effective immunologic responses to HPV infection appear to be
induced systemically and include (i) HPV type-speci®c, neutraliz-
ing antibody responses against the conformational epitopes of the
major capsid (L1) protein (Ghim et al, 1991; Frazer, 1996; Schiller
and Lowy, 1996), and (ii) cell-mediated immune responses against
viral antigenic determinants presented in the context of the major
histocompatibility complex-1 molecules (Chen et al, 1992;
Nakagawa et al, 1997). The latter appears to be responsible for
the spontaneous regression of HPV type-speci®c warts and
condylomata. Reactivity of a patient's serum with recombinant
virus-like particles has been reported in approximately 55%±70% of
patients with mucosal lesions that contain speci®c virus DNA
(Carter et al, 2000). A positive reaction probably results from
previous or concurrent HPV infections or spontaneous regression
of HPV-induced warts or condylomata. The signi®cance of a
negative reaction is unknown.
RESERVOIRS OF HPV INFECTION
The mucosotropic, novel, and EV HPV all appear capable of
establishing a latent state. The mucosotropic HPV establish a latent
infection in the basal cells of mucosal squamous epithelium
(Steinberg et al, 1983; Ferenczy et al, 1985). The novel and EV
viruses appear to establish a latent state in either the basal cells of
skin or another site in the hair follicle, either the bulge or the
infundibulum. The latter has been demonstrated in animal models
(Schmitt et al, 1996). The discovery of mucosotropic HPV in an
apparent latent state in plucked hair from the hair follicles that
de®ne cutaneous secondary sex characteristics, suggests that
hormonally responsive squamous epithelium of the skin may also
provide sites of latency for mucosotropic HPV (Boxman et al,
1999a). Latently infected squamous epithelium appears clinically
and histologically as normal tissue (Stubenrauch and Laimins,
1999).
Cutaneotropic, novel, and EV HPV Latent virus infections
are important because they represent a reservoir of viruses that
appear to establish a privileged state with respect to the immune
system. A competent immune system can prevent latent HPV
infections from becoming a wart or papilloma. Various cofactors,
many of which may be related to either transient or permanent
alterations in cell-mediated immunity, appear to reactivate these
viruses to produce a mucosal papilloma or, in the case of EV, a ¯at
macule. In EV the ¯at macules may become disseminated as the
degree of immunosuppression worsens with age, with those
exposed to sunlight having a 30% chance of developing into a
cancer. HPV-5 or -8 appear to be carcinogenic in EV patients
(Orth, 1986; P®ster, 1992), although the skin surrounding the
lesion appears to be teeming with large numbers of other HPV EV
types (Gassenmaier et al, 1984; Wieland et al, 1998; de Villiers et al,
1999). Because EV patients live in a small area in Eastern Europe
and only a few EV patients have been seen worldwide, the EV
viruses have been considered by many to be very interesting but
unique and out of the mainstream of clinical lesions caused by the
other HPV types.
Until recently (Astori et al, 1998; Boxman et al, 1997, 2000;
Harwood et al, 1999), attempts to identify the cutaneotropic novel
and EV viruses as putative latent infections in immunocompetent
individuals by molecular cloning techniques were largely unsuc-
cessful, evoking questions about the sites of infection and reservoirs
for these viruses. The only clinical evidence that these HPV are
present in normal individuals has been the presence of circulating
antibodies against the major capsid protein of patients with
nonmelanotic skin cancers, burns, and other lesions of the skin
characterized by proliferation of squamous epithelium (Jablonska et
al, 1978; Orth, 1986; Majewski and Jablonska, 1997).
Mucosotropic HPV Latent infections with the various
mucosotropic HPV infections appear to extend contiguously
outside the margin of active infection (Ferenczy et al, 1985).
Persistence of the latent infection, particularly in the larynx of
individuals who have had laryngeal papillomatosis, has been well
established (Steinberg et al, 1983; Maran et al, 1995). Deformed
largyngeal tissue, surgically removed years after the disease burned
out, has been shown to harbor latent HPV-11 infections.
Approximately 20% of all cutaneous warts and mucosal
condylomata do not undergo spontaneous natural regression and
are refractory to treatment (Bunney, 1982). The most effective
treatment appears to be treatment that causes in¯ammation at the
site of the wart or condylomata. Lesions that recur within 1 wk to
1 mo after treatment probably represent activation of a latent
infection such as recurrent laryngeal papillomatosis. Lesions that
recur after 6 wk of treatment most likely represent reinoculation. If
the lesion has not recurred by 6 mo, the patient is most likely
cured.
DETECTION OF NOVEL AND EV-LIKE HPV IN LATENT
AND ACTIVE INFECTION
Cloning and sequencing of papillomavirus (PV) genomes directly
from infectious lesions have established a site speci®city and the
malignant potential for many of the known PV genotypes that
infect the anogenital and oropharyngeal tracts and cutaneous
epithelium of immunocompetent individuals. The novel and EV
viruses are dif®cult to identify in normal and abnormal skin for two
reasons (Harwood et al, 1999, 2000). First, only a few of the cells of
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the hair follicle, skin, or dermatologic lesion appear to be infected,
most likely latently. As few as 1 in 100 cells from a particular site
have been estimated to harbor one copy of a particular HPV
genome. Second, although there are highly conserved regions of
the L1 protein, conservation occurs among the amino acid
sequences and not the codons that are necessary to encode each
amino acid. In fact, many silent nucleic acid mutations allow the
®delity of highly conserved amino acid sequences to be maintained
according to the genetic code; However, ampli®cation by PCR
depends highly on matching the base pairs of synthetic primers to
those of the viral DNA. A low copy number of HPV genome
equivalents (characteristic of latent infections) combined with the
most highly conserved amino acid regions of the L1 protein with
silent mutations, have made it dif®cult to design PCR primers
sensitive enough to identify the HPV type by PCR ampli®cation.
The reported ®ndings of signi®cantly increased prevalence of
antibodies against HPV-8 virus-like particles in patients with
squamous carcinoma and its precursor lesion, solar keratosis, suggest
that skin surgically removed from these areas should maintain
lesions productively infected by novel or EV-like HPV.
We previously screened different warty lesions of the skin and
mucosa for productive HPV infections by using polyclonal
antibodies produced against disrupted PV particles that recognize
PV genus-speci®c antigenic determinants. Positive intranuclear
staining in the granular cells of the squamous epithelium by
immunohistochemistry using this antibody is interpreted as being
positive for PV structural antigens and a productive HPV infection.
EXPERIMENTS
To determine whether we could identify productive HPV
infections in hyperplastic and neoplastic tissue from sun-exposed
areas of patients, we retrieved paraf®n blocks from the archival ®les
of the pathology department at Georgetown University. The
specimens were from the patients who had been diagnosed as
having squamous carcinoma and solar keratosis or seborrheic
keratosis. We included the latter because seborrehic keratosis-like
lesions in cats, large (leopards, panthers, etc.) and small (domestic),
are associated with productive infections by the feline PV
(Sundberg et al, 2000). Multiple step sections were cut from each
of 45 blocks that represented at least 15 squamous carcinomas, 15
basal carcinomas, and 15 lesions diagnosed as seborrheic keratosis.
Each section was stained with a cocktail of antibodies from three
rabbits immunized with disrupted bovine PV-1, disrupted canine
PV (CPV), and disrupted HPV-8 virus-like particles. Control
sections were cervical dysplasias previously shown to be positive for
HPV-6 productive infection, ¯at warts positive for HPV-3
productive infection, and canine oral papillomas positive for CPV
productive infection.
None of the cutaneous lesions exposed to ultraviolet light was
positive for PV structural viral antigens. All positive controls stained
positively. These results suggested that productive infection of the
skin by novel and EV viruses are sporadic, random, and not easily
detectable. We also concluded that most novel and EV infections of
the skin are latent. In situ hybridization may be more successful in
localizing HPV lesions that may be associated with nonmelanotic
skin cancers and their precursor lesions.
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